Mesa Lampré M Pilar Mesa
Hospital Nuestra Señora de Gracia, Zaragoza, España.
Rev Esp Geriatr Gerontol. 2011 Oct;46 Suppl 1:33-8. doi: 10.1016/j.regg.2011.10.007.
Progress in knowledge of the physiopathology of Alzheimer's disease over the last few decades has allowed much earlier diagnosis, even before the onset of clinical symptoms. Although the use of biomarkers is still far from being widespread and cannot be recommended outside research settings, their potential use has led to a review of the diagnostic criteria employed in the last few years. Among other criteria, asymptomatic and prodromal phases have been definitively incorporated into the spectrum of the disease and have been redefined. In future, the possibility of an earlier and more accurate diagnosis will allow the application of treatments acting in these phases, delaying progression to more advanced stages or even halting the disease before clinical manifestations develop. Currently, such treatments are still far from being a reality and interest in biomarkers centers on research since their detection could allow standardization of the samples used in clinical trials and exclusion of individuals showing signs of prodromal disease but who will never develop the disease.
在过去几十年里，阿尔茨海默病生理病理学的知识进展使得能够在更早阶段进行诊断，甚至在临床症状出现之前。尽管生物标志物的使用仍远未普及，且在研究环境之外不被推荐，但它们的潜在用途促使人们对过去几年采用的诊断标准进行了重新审视。在其他标准中，无症状期和前驱期已被明确纳入疾病谱并重新定义。未来，更早、更准确诊断的可能性将使针对这些阶段的治疗得以应用，延缓疾病进展至更晚期阶段，甚至在临床表现出现之前阻止疾病发展。目前，此类治疗仍远未成为现实，对生物标志物的关注主要集中在研究方面，因为其检测可使临床试验中使用的样本标准化，并排除那些显示前驱疾病迹象但永远不会发病的个体。
